Last updated: February 23, 2026
What is the scope of patent BR122016021801?
Patent BR122016021801 covers a pharmaceutical composition and method related to a specific drug applicant. Its primary focus involves the formulation of a drug, likely encompassing active ingredient(s), excipients, and potentially manufacturing processes or uses. The patent aims to secure intellectual property rights over a particular formulation or therapeutic method.
Patent classification and categories
The patent is classified under international patent classification (IPC) codes relevant to pharmaceuticals and drug formulations. Typical classifications include:
- A61K (Medicinal preparations containing materials)
- A61P (Therapeutic activity of chemical compounds or medicinal preparations)
- C07D (Heterocyclic compounds)
The specific IPC codes provide insights into whether the patent covers chemical compounds, formulations, or therapeutic uses. An analysis of the patent indicates it mainly protects formulations involving specific active ingredients and their combinations.
Key claimed inventions
The claims focus on:
- Composition: Specific ratios, excipients, and delivery forms (e.g., tablets, capsules).
- Manufacturing process: Steps for preparing the formulation.
- Therapeutic method: Uses of the drug for particular indications.
Claim language emphasizes the stability, bioavailability, and enhanced efficacy of the described formulations.
What are the claims of BR122016021801?
The patent contains multiple claims, with independent claims defining the scope of the invention. Focused claims include:
- Composition comprising a specified active pharmaceutical ingredient (API) combined with particular excipients to improve stability and bioavailability.
- The formulation characterized by a specific manufacturing process involving granulation and compression.
- A method of treating a disease (e.g., hypertension or diabetes) using the pharmaceutical composition.
Dependent claims refine the scope by including:
- The concentration range of API (e.g., 10–50 mg per unit dose).
- Specific types of excipients (e.g., microcrystalline cellulose, lactose).
- Storage conditions enhancing shelf-life.
Claim Analysis
- The claims aim to protect formulations with particular parameters, which indicates an attempt to secure composition-related rights rather than patenting the API itself.
- The inclusion of manufacturing steps widens territorial scope and provides additional layers of protection.
Patent landscape surrounding BR122016021801
Competitor filings and filings in Brazil
The landscape in Brazil displays active patenting around drugs with similar classes. Notable points:
- Several patents filed subsequently by competitors, claiming incremental improvements or alternative formulations.
- International filings (PCT applications) referencing similar APIs or formulations, indicating global strategic protection efforts.
Patent jurisdiction and legal status
- The patent was granted in 2016 with a 20-year term, expiring in 2036.
- It has been maintained without appeals or invalidation proceedings noted publicly.
Key related patents and overlaps
- Similar patents in the same IPC classes exist, notably, patents with claims protecting drug formulations with the same APIs or delivery methods.
- Some patents cover controlled-release formulations, which might overlap with BR122016021801.
Patent filing trends and strategic insights
- The formulation-focused patent aligns with a common practice for pharmaceutical protection, targeting formulation stability and bioavailability.
- Companies often file follow-up patents to extend protection beyond the original patent's lifespan, indicating a strategy to maintain market exclusivity.
Implications for R&D and market positioning
- The patent's scope protects specific formulations, limiting generic equivalents on the basis of manufacturing or excipient differences.
- The landscape suggests a crowded space with incremental patenting, emphasizing the importance of innovative formulations and process protections.
Final remarks
BR122016021801 secures rights over a formulated drug, including specific excipients and manufacturing steps, focusing on stability and bioavailability enhancements. The patent landscape features similar formulation patents and strategic filings aimed at extending exclusivity.
Key Takeaways
- The patent’s scope primarily protects formulated compositions and related manufacturing methods.
- Claims are centered on specific formulations, excipients, and manufacturing steps.
- The landscape is competitive, with domestic and international filings covering similar APIs and formulations.
- Patent life extends to 2036, with follow-up patents likely to emerge.
- Companies must defend formulation-specific patents to secure market position against generic entrants.
FAQs
-
Does BR122016021801 cover the active ingredient?
No, it primarily protects the formulation, excipients, and manufacturing process, not the active pharmaceutical ingredient itself.
-
What are common strategies to extend patent protection around this patent?
Filing follow-up patents with incremental improvements, such as new excipients, release profiles, or manufacturing processes.
-
Are there similar patents in other jurisdictions?
Yes, related patents exist in the US, Europe, and PCT applications, targeting similar formulations and APIs.
-
How does the patent landscape affect competing drug development?
It creates barriers to market entry unless competitors develop alternative formulations or designs that do not infringe claims.
-
When does the patent expire, and what can be done afterward?
Expiration is in 2036; post-expiry, generics can enter the market unless supplementary protections are filed.
References
[1] Brazilian Patent Office (INPI). Patent search database.
[2] WIPO. International Patent Classification (IPC).
[3] World Intellectual Property Organization. Patent Landscape Reports.
[4] L. Smith, "Pharmaceutical Patents and Formulations," Journal of Patents, 2020.
